1. Medtech Insight

Multiple Hacking Risks Found In Another Infusion Pump

After a hacker brought the issue to the attention of Smiths Medical, the company engaged US FDA and the Department of Homeland Security, which alerted users that Smith's Medfusion 4000 wireless syringe infusion pumps are at risk from multiple cybersecurity vulnerabilities.

Cybersecurity vulnerabilities discovered in several versions of Smiths Medical's Medfusion 4000 wireless syringe infusion pumps could allow malicious hackers to change their functionality and disable communications capability, the US Department of Homeland Security (DHS) said in an advisory issued late last week.

According to Smiths, the vulnerabilities were first discovered and reported to them by Scott Gayou, a security engineer at Garmin International in Kansas City, Mo. In response, the company contacted...

More from Regulation

Final Curtain For LDTs? FDA Will Not Appeal District Court Decision To Vacate Final Rule

 
• By Brian Bossetta

The US FDA has given up on its effort to regulate lab-developed tests as medical devices, at least for now. The agency will not appeal a decision from the Eastern District of Texas that tossed out the FDA’s final rule, leaving the agency with few cards.

EU Finalizes Framework For Joint Clinical Assessments Of High-Risk Devices

 
• By Amanda Maxwell

Second submission window for joint scientific consultations on a procedure to help prepare for joint clinical assessments will open from 2 to 30 June 2025.

UK Take Care! Regulatory And Market Access Reforms Must Not Shut Out Medtech Growth

 
• By Ashley Yeo

Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.

Zika Virus Test Among 4 New FDA Device Classifications

 
• By Elizabeth Orr

The FDA plans to announce class II status for four new device types, including tests for the Zika virus and genetic condition Fragile X. This follows earlier announcements and highlights a trend toward diagnostic classifications. The classifications are considered deregulatory, meaning they will hel

More from Policy & Regulation